Progressive multifocal leukoencephalopathy and newer biological agents.
about
Human polyomavirus reactivation: disease pathogenesis and treatment approachesNew insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathyTreatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsRole of immunosuppressive therapy for the treatment of multiple sclerosisConcordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targetsJC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?Animal Models for Progressive Multifocal LeukoencephalopathyProgressive multifocal leukoencephalopathy: clinical and molecular aspectsCurrent and emerging therapies in multiple sclerosis: a systematic reviewThe changing landscape of progressive multifocal leukoencephalopathy.PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.Infection risk in patients on multiple sclerosis therapeutics.Immunogenicity and other problems associated with the use of biopharmaceuticals.Vedolizumab for Crohn's disease.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabHeterologous immunity triggered by a single, latent virus in Mus musculus: combined costimulation- and adhesion- blockade decrease rejection.The human condition: an immunological perspective.Small-molecule inhibitors of JC polyomavirus infectionTreatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis.Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy.JC virus promoter/enhancers contain TATA box-associated Spi-B-binding sites that support early viral gene expression in primary astrocytes.Review article: BK virus in systemic lupus erythematosusA review on JC virus infection in kidney transplant recipients.Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphomaIncreased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study.Complications of immunosuppressive/immunomodulatory therapy in neurological diseases.Immune surveillance and response to JC virus infection and PML.Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.Infections associated with monoclonal antibody and fusion protein therapy in humans.The link between VLA-4 and JC virus reactivation.Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.Understanding and assessing potential serious adverse events: a practical approach to understanding the benefits and harm of psoriasis treatments.Progressive multifocal leukoencephalopathy in multiple sclerosis.T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.Immune reconstitution inflammatory syndrome associated with biologic therapy.The DNA damage response promotes polyomavirus JC infection by nucleus to cytoplasm NF- kappaB activation.Epigenetic regulation of polyomavirus JC involves acetylation of specific lysine residues in NF-κB p65.
P2860
Q21285083-57614119-7AC3-42DB-AE1C-86509E46D527Q26822247-0CA074FD-1F3E-46DC-A684-9E382A06A497Q26823444-02F0E01A-33BA-4558-96C8-585F4E682B7AQ26827467-9DC01F0F-D781-4487-B7BD-75D8196DD481Q26830569-93E7580C-B706-4DD7-AE2D-B29CF81BB4CAQ26852060-3F788AB6-7ACC-4EEB-AA05-EC6FA53B7D68Q26853218-7DE2801B-D1F8-465B-92B7-D1FEFE658000Q26858968-2241B13E-26A8-42A9-802A-2A5F07C35096Q29010983-B8731890-BC42-468B-8542-5847F18303E5Q30403035-2BFFD2D3-C1D2-4537-8B76-D249FE43E307Q30613846-ECCF8284-CDCD-4B5E-82A0-12809A5AA1D5Q30908652-861C2AF9-66A2-46A3-9A71-F7A43669F434Q33416851-DD88443B-816E-4669-B98B-AE471688C164Q34326912-835AF2AF-A399-425E-86E2-D7CDC747064AQ34818048-B292A859-526C-4A62-836D-DEF2D13D6BC8Q34937146-084000A1-53A7-4732-8574-29C4A4C61C82Q35188878-C40ADE78-1C73-46D4-856D-684796121D81Q35529977-A3B29070-492B-4173-8A66-0C2C21ABBB58Q35654037-FDE5B8F8-9E18-48DA-99E2-503D6C8DC55AQ35675602-8B7C7CE0-4C0B-492F-A792-28785639D618Q35899152-AD4B663C-42AF-4006-BD1D-095819B48D3CQ35960553-33CC5AA3-5406-4124-9608-966B4414C29CQ35986282-05637FCB-D433-46DF-B6E4-7FC0DAC75EA9Q36602840-73693F0B-3795-456F-94A3-7CB8F785AADFQ36703691-4A63E72E-6EF9-4CE0-8D53-3B5C8D529736Q36885632-7978BE0B-8E94-4F9A-8266-AC58C9895513Q37013065-C7D5C7AB-F253-4A61-844A-D6282013FBF5Q37678580-ACF2C5CC-0D96-45B2-8061-2E7F70492F53Q37703514-A1B8AC2B-0C8F-4FBD-8F45-BEF36BA4A07EQ37912944-A02D5788-CC5B-45BD-9EE5-CDDF78E0E72AQ37965603-77689176-7BA4-4DDC-8320-ED47ECEDD8D9Q37980042-C4B9C433-44B7-4764-9E7A-7F0ECFD995D1Q37980484-068A4B9A-ED9B-4360-B306-6A542AA292D7Q38106807-8BA5CEF8-C70A-41C7-8D95-6148DCD6A1C2Q38153637-D181847A-19EC-4B96-AA90-26985B5D6E1BQ38181018-27F9CDB2-CF80-45B3-9D4C-769587D9EF1AQ38268951-0E1CEA10-35F8-47CB-8133-198B008F21C0Q38287572-993D77FC-444F-4925-B465-E7B3243A609EQ38716372-983D3C8E-F18B-4581-AD7F-A93351359637Q38897401-2546C15C-33F0-4AC0-AD2F-EA3E04965485
P2860
Progressive multifocal leukoencephalopathy and newer biological agents.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Progressive multifocal leukoencephalopathy and newer biological agents.
@en
Progressive multifocal leukoencephalopathy and newer biological agents.
@nl
type
label
Progressive multifocal leukoencephalopathy and newer biological agents.
@en
Progressive multifocal leukoencephalopathy and newer biological agents.
@nl
prefLabel
Progressive multifocal leukoencephalopathy and newer biological agents.
@en
Progressive multifocal leukoencephalopathy and newer biological agents.
@nl
P1433
P1476
Progressive multifocal leukoencephalopathy and newer biological agents.
@en
P2093
Joseph R Berger
P304
P356
10.2165/11537510-000000000-00000
P577
2010-11-01T00:00:00Z
P6179
1044609260